GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » EBIT

CERo Therapeutics Holdings (CERo Therapeutics Holdings) EBIT : $ Mil (TTM As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings EBIT?

CERo Therapeutics Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2022 was $-11.97 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CERo Therapeutics Holdings's annualized ROC % for the quarter that ended in Dec. 2022 was -218.33%. CERo Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -268.26%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

CERo Therapeutics Holdings EBIT Historical Data

The historical data trend for CERo Therapeutics Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings EBIT Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
EBIT
-11.62 -11.97

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
EBIT -11.62 -11.97

Competitive Comparison of CERo Therapeutics Holdings's EBIT

For the Biotechnology subindustry, CERo Therapeutics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's EV-to-EBIT falls into.


CERo Therapeutics Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings  (NAS:CERO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CERo Therapeutics Holdings's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

ROC % (Q: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2021 ) + Invested Capital (Q: Dec. 2022 ))/ count )
=-11.971 * ( 1 - 0% )/( (6.001 + 4.965)/ 2 )
=-11.971/5.483
=-218.33 %

where

Invested Capital(Q: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=24.176 - 0.489 - ( 19.217 - max(0, 1.838 - 19.524+19.217))
=6.001

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11.349 - 0.472 - ( 6.82 - max(0, 1.164 - 7.076+6.82))
=4.965

Note: The Operating Income data used here is one times the annual (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

CERo Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2021  Q: Dec. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.971/( ( (4.652 + max(-0.946, 0)) + (4.273 + max(-0.236, 0)) )/ 2 )
=-11.971/( ( 4.652 + 4.273 )/ 2 )
=-11.971/4.4625
=-268.26 %

where Working Capital is:

Working Capital(Q: Dec. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.307) - (0.489 + 0 + 0.764)
=-0.946

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.256) - (0.472 + 0 + 0.02)
=-0.236

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CERo Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2022 )
=/21.233
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings EBIT Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » EBIT
Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
Website
https://www.cero.bio
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024